This study aims to compare salivary IL-6, MMP-8, MMP-9, and TIMP-1 levels between healthy children and caries-active children, and to evaluate the effects of 5% sodium fluoride (NaF) varnish and 2% chlorhexidine (CHX) used in caries prevention on these biomarkers.
The study will be conducted at Alanya Alaaddin Keykubat University, Faculty of Dentistry, Department of Pediatric Dentistry. Informed consent will be obtained from children and their parents/guardians. Investigator calibration will be performed using Cohen's kappa method prior to data collection. Sample size was calculated assuming 80% power (1-β = 0.80), α = 0.05, and Cohen's d ≈ 0.8, resulting in 20 participants per group using G*Power 3.1 software.
Study groups: Group A: 5% NaF varnish. Group B: 2% CHX + 5% NaF varnish. Group C: Standard oral hygiene education (negative control). Group D: Caries-free children (biological reference; baseline saliva sampling only).
Saliva samples will be collected at T0 (baseline), T1 (30 minutes post-application), and T2 (1 month). Unstimulated whole saliva will be collected, centrifuged at 5,000 g for 10 minutes at 4°C, and stored at -80°C. IL-6, MMP-8, MMP-9, and TIMP-1 levels will be measured using CE-marked/FDA-approved human saliva ELISA kits.

开始日期2026-05-15

申办/合作机构

Alanya Alaaddin Keykubat Üniversitesi

[+1]

NCT07611123

/ CompletedN/A

Effect of a Bioactive Mineral-Ionic Mouthrinse on Periodontal Soft Tissue Healing and Postoperative Pain After Tooth Extraction: A Double-Blind Randomized Clinical Trial

This randomized, double-blinded clinical trial was designed to evaluate the effects of a bioactive mineral-ionic mouthrinse (THERAVEX® Total Oral Care Plus) on postoperative healing and patient comfort following simple tooth extraction. Tooth extraction is one of the most common dental procedures and is frequently associated with postoperative pain, inflammation, and delayed soft tissue healing. Conventional mouthrinses such as chlorhexidine are widely used for their antimicrobial properties; however, alternative approaches aimed at supporting the physiological healing process are increasingly being investigated.
A total of 94 systemically healthy patients requiring simple tooth extraction were enrolled and randomly allocated into three parallel groups receiving either a bioactive mineral-ionic mouthrinse, chlorhexidine 0.12%, or normal saline as postoperative oral rinses. Participants and investigators were blinded to group allocation throughout the study period.
The primary objective of the study was to assess early soft tissue healing of the extraction socket using standardized clinical measurements of buccolingual (BL) and mesiodistal (MD) socket dimensions at different postoperative time points. Secondary objectives included the evaluation of postoperative pain using a visual analog scale (VAS), as well as clinical assessment of tissue response during the healing period.
The study aims to investigate whether a bioactive mineral-ionic oral rinse may serve as a supportive postoperative strategy for enhancing early wound healing and improving patient-reported comfort after dental extraction procedures

开始日期2026-04-28

申办/合作机构

King Abdulaziz University

NCT07453069

/ Not yet recruiting临床2期

A Randomized, Double-blind, Three Arm, Multi-center Phase 2 Study to Investigate the Molecular Efficacy and Safety of FB301/Chlorhexidine Compared With FB301/Sham and Placebo/Sham in a Mock FET Cycle in Female Participants 18-40 Years of Age With Asymptomatic Vaginal Molecular Dysbiosis Planning to Undergo a Frozen Embryo Transfer (FET) Cycle

The goal of this clinical trial is to evaluate FB301 during a mock frozen embryo transfer (FET) cycle in pre-menopausal women aged 18 to 40 years with a prior failed FET and a defined vaginal bacterial imbalance (dysbiosis).
The main question it aims to answer is:
• Does treatment with FB301 during a mock FET cycle change the proportion of participants who meet the predefined vaginal bacterial threshold compared with placebo?
Researchers will compare:
* FB301 given after an initial vaginal cleansing with chlorhexidine (an antiseptic solution),
* FB301 given after an initial vaginal cleansing with saline (saltwater), and
* A placebo capsule given after an initial vaginal cleansing with saline to determine whether these approaches affect vaginal bacterial composition and pregnancy outcomes.
Participants will take study treatment for 15 days during a "mock" FET cycle. In a mock cycle, participants receive the hormones needed to prepare the uterus for embryo transfer, but no embryo is transferred. After completing the mock cycle, participants will proceed with their planned frozen embryo transfer and will be followed during pregnancy until birth.
Participants will:
* Undergo a vaginal cleansing before receiving the first dose of FB301 or placebo
* Provide vaginal swab samples at up to 5 study visits
* Attend the study centre for up to 8 visits and participate in up to 4 follow-up phone calls
* Complete a mock FET cycle before proceeding with their planned frozen embryo transfer cycle
Participants who become pregnant will be followed until birth.

开始日期2026-04-15

申办/合作机构

Freya Biosciences ApS

[+1]

100 项与葡萄糖氯己定相关的临床结果

登录后查看更多信息

100 项与葡萄糖氯己定相关的转化医学

登录后查看更多信息

100 项与葡萄糖氯己定相关的专利（医药）

登录后查看更多信息

6,262

项与葡萄糖氯己定相关的文献（医药）

2026-10-01·Intensive and Critical Care Nursing

Effectiveness of chlorhexidine gluconate–impregnated dressings in preventing central line–associated bloodstream infection in a paediatric intensive care unit: A randomised controlled trial

Article

作者: Portero-Prados, Francisco Javier ; Pabón-Carrasco, Manuel ; Ponce-Blandón, José Antonio

OBJECTIVES:

To compare the effectiveness and dermatological safety of chlorhexidine gluconate (CHG)-impregnated dressings versus conventional transparent dressings in preventing central line-associated bloodstream infection (CLABSI) in paediatric patients admitted to a PICU.

METHODS:

A single-blind, randomised controlled trial with a 1:1 allocation ratio was conducted in a tertiary PICU. A total of 250 paediatric patients with a central venous catheter were included (125 per group). Patient characteristics, catheter-related variables, catheter dwell time and skin alterations were recorded. The primary outcome was CLABSI, defined according to CDC/NHSN criteria. Bivariate analyses and multivariable logistic regression were performed, including clinically relevant covariates related to catheter exposure, dressing type, and vaccination status. The trial was registered at ClinicalTrials.gov (NCT07175116).

RESULTS:

CLABSI incidence was significantly lower in the CHG group compared with the conventional dressing group (2.4% vs. 18.4%; p < 0.001). In multivariable analysis, CHG-impregnated dressings were independently associated with reduced CLABSI risk (OR = 0.15; 95% CI: 0.04-0.58). Longer catheter dwell time (OR = 1.13 per day; 95% CI: 1.04-1.22) and absence of complete vaccination (OR = 8.68; 95% CI: 2.48-30.47) were also associated with increased infection risk. Incomplete vaccination showed a similar trend without reaching statistical significance (OR = 6.48; 95% CI: 0.95-44.20). Skin alterations were more frequent in the CHG group (16.8% vs. 11.2%), predominantly in younger infants.

CONCLUSIONS:

CHG-impregnated dressings were associated with a significant reduction in CLABSI incidence in critically ill paediatric patients, although their use was linked to a modest increase in mild skin reactions.

IMPLICATIONS FOR CLINICAL PRACTICE:

CHG-impregnated dressings may be considered as part of a multifaceted infection prevention strategy, alongside appropriate catheter management, minimisation of catheter manipulation and proactive skin monitoring, with cautious and individualised use in infants.

2026-08-01·JOURNAL OF SURGICAL RESEARCH

Intra-Abdominal 0.05% Chlorhexidine Gluconate Lavage in Perforated Appendicitis

Article

作者: Keesari, Rohali ; Hwang, Rosa ; Dao, Duy T ; Kozlowski, Gabrielle ; Mudreac, Andrew ; Mattei, Peter

INTRODUCTION:

In August 2021, pediatric surgeons at our institution began using 0.05% chlorhexidine gluconate (CHG) solution in sterile water for intraoperative lavage during laparoscopic appendectomies. The goal of this study is to determine the efficacy of intraoperative lavage with 0.05% CHG in preventing surgical site infection (SSI) after appendectomy for pediatric perforated appendicitis.

METHODS:

The Electronic Medical Record was queried to identify patients aged <18 y who underwent laparoscopic appendectomy for perforated appendicitis between January 2018 and February 2025 at our institution. Demographics, preoperative laboratory values, and postoperative complications were compared between patients who did and did not receive 0.05% CHG lavage. Postoperative outcomes, including the rates of deep/organ-space SSI requiring a drainage procedure, inpatient readmission, return to operating room, and emergency department revisits, were compared between treatment and control groups with Firth logistic regression and inverse probability of treatment weighting.

RESULTS:

A total of 858 cases of laparoscopic appendectomy for perforated appendicitis were identified; 0.05% CHG lavage was used in 197 (23.0%). Postoperative drainage rate with and without 0.05% CHG lavage was 5.1% and 8.5%, respectively. Using Firth logistic regression and after adjustment for demographic variables and preoperative laboratory values, intraoperative 0.05% CHG lavage did not significantly impact the rate of deep/organ-space SSI requiring drainage procedure (adjusted odds ratio [OR]: 0.58, 95% confidence interval [CI: 0.29, 1.14]), inpatient readmission (OR: 1.40, 95% CI [0.77, 2.56]), return to the operating room (OR: 1.14, 95% CI [0.40, 3.29]), or emergency department revisit (OR: 1.19, 95% CI [0.71, 1.97]). Sensitivity analysis using inverse probability of treatment weighting was consistent with the primary Firth logistic regression analyses.

CONCLUSIONS:

A 0.05% CHG lavage during laparoscopic appendectomy for perforated appendicitis was associated with a low rate of deep/organ-space SSI requiring drainage (5%). However, it does not significantly alter postoperative outcomes. Prospective studies are needed to evaluate whether this solution lowers infectious complications.

2026-07-01·JOURNAL OF HOSPITAL INFECTION

Antimicrobial persistence for 10 days after antiseptic skin preparation in healthy volunteers

Article

作者: Bashir, Muhammad ; Nordby, Tera ; Morse, Dan ; Hollingsworth, Angela ; Hanson, Tiffany

Antiseptic agents reduce skin microbes and aid in the prevention of surgical site infections (SSIs). This report describes a study performed in 66 healthy volunteers to assess the persistent antimicrobial efficacy of a commercially available skin antiseptic composed of 2% CHG and 70% isopropyl alcohol (IPA). The solution was applied to the abdominal and inguinal (groin) regions and was allowed to dry before being assessed for immediate effect and covered with dressings. The antimicrobial persistence was examined at different time points over ten days post-application and the reduction in skin bacterial levels (CFU/cm²) from baseline was assessed. The mean Log₁₀ reduction in bacteria on the abdomen was 2.75 at 10 minutes, 2.03 at 7 days, and 1.53 at 10 days post-application. The mean Log₁₀ reduction in skin bacteria on the groin was 3.59 at 10 minutes, 2.80 at 7 days, and 2.42 at 10 days post-application. The results showed that the antimicrobial effect of this skin prep can be sustained for 10 days post-application when used on healthy volunteers. Further studies are needed to determine the antimicrobial persistence and effect on SSIs when this antiseptic agent is used preoperatively.

项与葡萄糖氯己定相关的新闻（医药）

2026-06-10

·信狐药迅

三个国产1类新药：豪森奥莱泊肽、信达IBI343和上海宝济KJ103提交上市申请|新受理（6.1-6.7）

本周药品注册受理数据，分门别类呈现，一目了然。(6.1-6.7）新药上市申请药品名称企业注册分类受理号奥莱泊肽注射液江苏豪森药业集团有限公司 1 CXHS2600084 奥莱泊肽注射液江苏豪森药业集团有限公司 1 CXHS2600082 奥莱泊肽注射液江苏豪森药业集团有限公司 1 CXHS2600080 奥莱泊肽注射液江苏豪森药业集团有限公司 1 CXHS2600083 奥莱泊肽注射液江苏豪森药业集团有限公司 1 CXHS2600081 奥莱泊肽注射液江苏豪森药业集团有限公司 1 CXHS2600079 缬沙坦左氨氯地平片江苏永安制药有限公司 2.3 CXHS2600078 IBI343 信达生物医药科技(杭州)有限公司 1 CXSS2600088 注射用KJ103 上海宝济药业股份有限公司 1 CXSS2600089 新药临床申请药品名称企业注册分类受理号 SYH2092注射液石药集团巨石生物制药有限公司 1 CXHL2600674 NH302注射液江苏恩华药业股份有限公司 1 CXHL2600673 NH130枸橼酸盐片江苏恩华药业股份有限公司 1 CXHL2600672 NH130枸橼酸盐片江苏恩华药业股份有限公司 1 CXHL2600671 NH130枸橼酸盐片江苏恩华药业股份有限公司 1 CXHL2600670 NH130枸橼酸盐片江苏恩华药业股份有限公司 1 CXHL2600669 RZ-520雾化吸入溶液宁康晓维生物制药(浙江)有限公司 1 CXHL2600675 HCXT-2001片(A) 上海瀚辰星泰医药科技有限公司 1 CXHL2600652 HCXT-2001片(A) 上海瀚辰星泰医药科技有限公司 1 CXHL2600651 HRS-3095片成都盛迪医药有限公司 1 CXHL2600656 HSK51155片海思科医药集团股份有限公司 1 CXHL2600650 HSK51155片海思科医药集团股份有限公司 1 CXHL2600648 HSK51155片海思科医药集团股份有限公司 1 CXHL2600647 HRS-3095片成都盛迪医药有限公司 1 CXHL2600655 HRS-3095片成都盛迪医药有限公司 1 CXHL2600654 HRS-3095片成都盛迪医药有限公司 1 CXHL2600653 ZL-65片成都赜灵生物医药科技股份有限公司 1 CXHL2600659 ZL-65片成都赜灵生物医药科技股份有限公司 1 CXHL2600658 ZL-65片成都赜灵生物医药科技股份有限公司 1 CXHL2600657 HSK51155片海思科医药集团股份有限公司 1 CXHL2600649 APH04935片广州一品红制药有限公司 1 CXHL2600662 APH04935片广州一品红制药有限公司 1 CXHL2600661 APH04935片广州一品红制药有限公司 1 CXHL2600660 磷酸ORIC-1327滴眼液成都华森奥睿药业有限公司 1 CXHL2600668 磷酸ORIC-1327滴眼液成都华森奥睿药业有限公司 1 CXHL2600667 磷酸ORIC-1327滴眼液成都华森奥睿药业有限公司 1 CXHL2600666 磷酸ORIC-1327滴眼液成都华森奥睿药业有限公司 1 CXHL2600665 磷酸ORIC-1327滴眼液成都华森奥睿药业有限公司 1 CXHL2600664 磷酸ORIC-1327滴眼液成都华森奥睿药业有限公司 1 CXHL2600663 DC7001A胶囊北京双鹤润创科技有限公司 1 CXHL2600645 DC7001A胶囊北京双鹤润创科技有限公司 1 CXHL2600646 DC7001A胶囊北京双鹤润创科技有限公司 1 CXHL2600644 DC7001A胶囊北京双鹤润创科技有限公司 1 CXHL2600643 伊匹乌肽散剂温州益承睛湛生物科技有限公司 1 CXHL2600642 注射用APG-1252 苏州亚盛药业有限公司 1 CXHL2600641 TRI-611片诺为泰医药科技(上海)有限公司 1 CXHL2600640 TRI-611片诺为泰医药科技(上海)有限公司 1 CXHL2600639 YZEE03冲洗液益洲海洋生物科技(山东)有限公司 2.3 CXHL2600676 六价重组诺如病毒疫苗(汉逊酵母) 华北制药金坦生物技术股份有限公司 1.1 CXSL2600598 六价重组诺如病毒疫苗(汉逊酵母) 华北制药金坦生物技术股份有限公司 1.1 CXSL2600597 LM101注射液北京联立众达医疗科技有限公司 1 CXSL2600608 SCTB41注射液神州细胞工程有限公司 1 CXSL2600607 SCTB41注射液神州细胞工程有限公司 1 CXSL2600606 注射用DXC016 杭州多禧生物科技有限公司 1 CXSL2600610 EX103注射液广州爱思迈生物医药科技有限公司 1 CXSL2600609 HY001N细胞注射液合源生物科技股份有限公司 1 CXSL2600604 注射用AK0406 上海爱科百发生物医药技术股份有限公司 1 CXSL2600596 奥妥珠单抗β注射液北京天广实生物技术股份有限公司 1 CXSL2600595 注射用HMPL-A830 和记黄埔医药(上海)有限公司 1 CXSL2600599 QLS2404注射液齐鲁制药有限公司 1 CXSL2600601 QLS2404注射液齐鲁制药有限公司 1 CXSL2600600 MG-K10人源化单抗注射液湖南麦济生物技术股份有限公司 1 CXSL2600603 VG712注射液成都维瑾柏鳌生物医药科技有限公司 1 CXSL2600592 注射用MC002 杭州麦联科生物医药有限公司 1 CXSL2600590 注射用重组抗PD1/TIM3人源化双特异抗体健信生物科技(宁波)有限公司 1 CXSL2600591 注射用LB4330 健信生物科技(宁波)有限公司 1 CXSL2600593 IBI3014 信达生物制药(苏州)有限公司 1 CXSL2600594 SHR-1179注射液广东恒瑞医药有限公司 1 CXSL2600586 GR2302注射液智翔(上海)医药科技有限公司 1 CXSL2600587 GR2302注射液(皮下注射) 智翔(上海)医药科技有限公司 1 CXSL2600588 GR2302注射液(皮下注射) 智翔(上海)医药科技有限公司 1 CXSL2600589 仿制药申请药品名称企业注册分类受理号注射用盐酸兰地洛尔朗天药业(湖北)有限公司 3 CYHS2601314 维生素K1注射液江苏润恒制药有限公司 3 CYHS2601318 洛索洛芬钠口服溶液山东丹红制药有限公司 3 CYHS2601315 注射用西维来司他钠重庆莱美药业股份有限公司 3 CYHS2601320 右酮洛芬氨丁三醇口服溶液北京远方通达医药技术有限公司 3 CYHS2601290 己酮可可碱缓释片黑龙江亿达鸿药业有限公司 3 CYHS2601283 复方匹可硫酸钠颗粒浙江金华康恩贝生物制药有限公司 3 CYHS2601269 盐酸二甲双胍缓释片(IV) 北京双鹭药业股份有限公司 3 CYHS2601267 呋塞米口服溶液联环药业(安庆)有限公司 3 CYHS2601264 盐酸曲唑酮口服溶液北京远方通达医药技术有限公司 3 CYHS2601262 硫辛酸片北京双鹭药业股份有限公司 3 CYHS2601259 呋塞米注射液江西泰吉立生物制药有限公司 3 CYHS2601301 聚普瑞锌颗粒安徽佳和药业有限公司 3 CYHS2601298 布洛芬颗粒江苏联环药业股份有限公司 3 CYHS2601260 注射用甲磺酸萘莫司他烟台东诚北方制药有限公司 3 CYHS2601294 吡拉西坦注射液许昌未来制药有限责任公司 3 CYHS2601278 碳酸氢钠血滤置换液(无钾、无钙、0.6mmol/L镁) 石家庄四药有限公司 3 CYHS2601304 碳酸氢钠血滤置换液石家庄四药有限公司 3 CYHS2601295 硫酸沙丁胺醇口服溶液北京民康百草医药科技有限公司 3 CYHS2601282 注射用盐酸兰地洛尔四川奥邦古得药业有限公司 3 CYHS2601276 盐酸氯普鲁卡因注射液福安药业集团宁波天衡制药有限公司 3 CYHS2601281 对乙酰氨基酚维生素C泡腾片南京海纳制药有限公司 3 CYHS2601286 头孢呋辛酯干混悬剂福安药业集团庆余堂制药有限公司 3 CYHS2601293 注射用西维来司他钠重庆华邦制药有限公司 3 CYHS2601279 磷酸二氢钠磷酸氢二钠颗粒伊春康尔心药业有限公司 3 CYHS2601253 氨溴特罗口服溶液江西半边天药业有限公司 3 CYHS2601258 盐酸氯普鲁卡因注射液北京紫萌医药科技有限公司 3 CYHS2601220 盐酸氯普鲁卡因注射液北京紫萌医药科技有限公司 3 CYHS2601219 右酮洛芬氨丁三醇注射液中润药业有限公司 3 CYHS2601218 普罗布考片宁夏康亚药业股份有限公司 3 CYHS2601226 中性低钙腹膜透析液(碳酸氢盐-G2.5%) 广东科泓药业有限公司 3 CYHS2601230 盐酸氯普鲁卡因注射液成都瑞尔医药科技有限公司 3 CYHS2601237 葡萄糖酸氯己定含漱液北京远方通达医药技术有限公司 3 CYHS2601233 复合磷酸氢钾注射液仁合益康汇泽药业河北有限公司 3 CYHS2601232 盐酸异丙嗪注射液亚宝药业集团股份有限公司 3 CYHS2601244 盐酸异丙嗪注射液亚宝药业集团股份有限公司 3 CYHS2601243 聚卡波非钙片浙江佐力药业股份有限公司 3 CYHS2601241 注射用盐酸兰地洛尔宜昌人福药业有限责任公司 3 CYHS2601236 注射用西维来司他钠山东豪瑞恩制药有限公司 3 CYHS2601242 富马酸伏诺拉生片广东彼迪药业有限公司 4 CYHS2601313 富马酸伏诺拉生片广东彼迪药业有限公司 4 CYHS2601312 盐酸达泊西汀片四川依科制药有限公司 4 CYHS2601311 盐酸达泊西汀片四川依科制药有限公司 4 CYHS2601310 醋酸阿比特龙片湖北亨迪药业股份有限公司 4 CYHS2601309 醋酸阿比特龙片湖北亨迪药业股份有限公司 4 CYHS2601308 维生素K1注射液江苏润恒制药有限公司 4 CYHS2601319 富马酸伏诺拉生片江苏恒沣药业有限公司 4 CYHS2601317 富马酸伏诺拉生片江苏恒沣药业有限公司 4 CYHS2601316 他克莫司缓释胶囊华北制药股份有限公司 4 CYHS2601291 盐酸氨溴索口服溶液哈尔滨葵花药业有限公司 4 CYHS2601288 雷米普利片江苏德源药业股份有限公司 4 CYHS2601280 左奥硝唑氯化钠注射液北京亿灵医药科技发展有限公司 4 CYHS2601275 盐酸莫西沙星氯化钠注射液安徽省先锋制药有限公司 4 CYHS2601272 二十碳五烯酸乙酯软胶囊河南君善生物技术有限公司 4 CYHS2601271 二十碳五烯酸乙酯软胶囊河南君善生物技术有限公司 4 CYHS2601270 单硝酸异山梨酯片山东博瀚制药有限公司 4 CYHS2601266 艾普拉唑肠溶片广东安诺药业股份有限公司 4 CYHS2601261 艾普拉唑肠溶片江苏和晨药业有限公司 4 CYHS2601265 依达拉奉右莰醇注射用浓溶液内蒙古白医制药股份有限公司 4 CYHS2601263 注射用氨曲南阿维巴坦钠上海上药新亚药业有限公司 4 CYHS2601299 玛巴洛沙韦片湘北威尔曼制药股份有限公司 4 CYHS2601297 玛巴洛沙韦片湘北威尔曼制药股份有限公司 4 CYHS2601296 他克莫司缓释胶囊华北制药股份有限公司 4 CYHS2601292 多替诺雷片江苏德源药业股份有限公司 4 CYHS2601287 多替诺雷片江苏德源药业股份有限公司 4 CYHS2601285 褪黑素颗粒江西施美药业股份有限公司 4 CYHS2601277 二甲硅油乳剂重庆大健能制药有限公司 4 CYHS2601274 二甲硅油乳剂重庆大健能制药有限公司 4 CYHS2601273 布地奈德肠溶胶囊陕西丽彩药业有限公司 4 CYHS2601268 氟伐他汀钠缓释片南京易亨制药有限公司 4 CYHS2601303 莫匹罗星软膏江西普丽尔药业有限公司 4 CYHS2601302 达格列净片扬子江药业集团上海海尼药业有限公司 4 CYHS2601300 注射用头孢他啶阿维巴坦钠苏州东瑞制药有限公司 4 CYHS2601307 美阿沙坦钾片苏州弘森药业股份有限公司 4 CYHS2601306 美阿沙坦钾片苏州弘森药业股份有限公司 4 CYHS2601305 聚乙烯醇滴眼液南京海纳制药有限公司 4 CYHS2601284 艾普拉唑肠溶片河北龙海药业股份有限公司 4 CYHS2601289 硝呋太尔制霉菌素阴道软胶囊烟台鲁银药业有限公司 4 CYHS2601247 西格列汀二甲双胍片(II) 江西杏林白马药业股份有限公司 4 CYHS2601246 苯磺酸左氨氯地平片江苏迪赛诺制药有限公司 4 CYHS2601245 盐酸羟考酮缓释片萌蒂(中国)制药有限公司 4 CYHS2601252 盐酸羟考酮缓释片萌蒂(中国)制药有限公司 4 CYHS2601251 盐酸二甲双胍缓释片河北新石制药有限公司 4 CYHS2601250 盐酸二甲双胍缓释片河北新石制药有限公司 4 CYHS2601249 盐酸二甲双胍缓释片河北新石制药有限公司 4 CYHS2601248 甲钴胺片浙江易泽达医药科技有限公司 4 CYHS2601257 多替诺雷片四川国为制药有限公司 4 CYHS2601256 多替诺雷片四川国为制药有限公司 4 CYHS2601255 蒙脱石散山东司邦得制药有限公司 4 CYHS2601254 阿达帕林凝胶乐福思健康产业股份公司 4 CYHS2601221 蒙脱石混悬液山东新华制药股份有限公司 4 CYHS2601217 ω-3脂肪酸乙酯90软胶囊成都诺和晟鸿生物制药有限公司 4 CYHS2601216 注射用硫酸艾沙康唑山东鲁抗医药股份有限公司 4 CYHS2601214 达格列净片江苏欧歌制药有限公司 4 CYHS2601229 达格列净片江苏欧歌制药有限公司 4 CYHS2601228 艾拉莫德片沈阳欣瑞制药有限公司 4 CYHS2601227 甲硝唑凝胶河南大新药业有限公司 4 CYHS2601225 甲硝唑凝胶遂成药业股份有限公司 4 CYHS2601224 甲硝唑凝胶遂成药业股份有限公司 4 CYHS2601223 甲硝唑凝胶遂成药业股份有限公司 4 CYHS2601222 阿昔替尼片南京正大天晴制药有限公司 4 CYHS2601231 苯磺酸美洛加巴林片湖南一格制药有限公司 4 CYHS2601235 苯磺酸美洛加巴林片湖南一格制药有限公司 4 CYHS2601234 甲硝唑凝胶山东辰欣佛都药业股份有限公司 4 CYHS2601215 阿达帕林过氧苯甲酰凝胶乐福思健康产业股份公司 4 CYHS2601240 脂肪乳氨基酸(17)葡萄糖(11%)注射液四川太平洋药业有限责任公司 4 CYHS2601239 甲钴胺片山东司邦得制药有限公司 4 CYHS2601238 氟[18F]代雌二醇注射液北京诺核动力医药科技有限公司 3 CYHL2600069 达雷妥尤单抗注射液(皮下注射) 正大天晴药业集团南京顺欣制药有限公司 3.3 CXSL2600605 进口申请药品名称企业注册分类受理号夫曲司兰钠注射液 Alnylam Netherlands B.V. 5.1 JXHS2600058 注射用硫酸甲苯磺酸头孢德罗 Shionogi & Co., Ltd. 5.1 JXHS2600060 夫曲司兰钠注射液 Alnylam Netherlands B.V. 5.1 JXHS2600059 奥妥珠单抗注射液 Roche Pharma (Schweiz) AG 2.2 JXSS2600048 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B. V. 2.2 JXSS2600047 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B. V. 2.2 JXSS2600046 尼卡利单抗注射液 Janssen-Cilag International NV 2.2 JXSS2600045 尼卡利单抗注射液 Janssen-Cilag International NV 2.2 JXSS2600044 帕博利珠单抗注射液 MSD International Business GmbH 3.1 JXSS2600049 LY4257496注射液 Eli Lilly and Company 1 JXHL2600193 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600203 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600202 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600201 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600200 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600196 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600195 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600194 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600205 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600204 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600199 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600198 Orforglipron片 Eli Lilly and Company 2.4 JXHL2600197 Elamipretide 注射液 Stealth BioTherapeutics Inc. 5.1 JXHL2600206 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600139 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600138 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600136 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600135 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600134 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600133 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600132 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600131 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600130 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600129 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600128 NNC0487-0111注射液 Novo Nordisk A/S 1 JXSL2600127 ABBV-706注射用冻干粉 AbbVie Inc. 1 JXSL2600126 ABBV-1758注射液 AbbVie Inc. 1 JXSL2600125 度伐利尤单抗注射液 Medlmmune LLC 2.2 JXSL2600137 伊奈利珠单抗注射液 Amgen Inc. 2.2 JXSL2600124 中药相关申请药品名称企业注册分类受理号安体威颗粒天士力医药集团股份有限公司 1.1 CXZS2600029 三花清解颗粒广东方盛融科药业有限公司 1.1 CXZL2600051 泻白散颗粒西施兰(南阳)药业股份有限公司 3.1 CXZS2600028 注射用AS006 中国科学院上海药物研究所 1.2 CXZL2600053 AS006 中国科学院上海药物研究所 1.2 CXZL2600052 灵莲花颗粒浙江佐力药业股份有限公司 2.3 CXZL2600050 真武汤颗粒武汉康乐药业股份有限公司 3.1 CXZS2600030 注：绿色字体部分为潜在首仿品种；咸达数据2026年1月每月药讯已出！关注“咸达数据”，微信关键词回复 ” 年+月，如202601” 获得最新药迅！不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

2026-05-25

·Science Daily

Beet juice lowers blood pressure in older adults in just 2 weeks

Drinking nitrate-rich beetroot juice may do more than support heart health — it could actually reshape the bacteria living in the mouth in ways that help lower blood pressure in older adults. In the largest study of its kind, researchers found that older people who drank concentrated beetroot juice twice daily for two weeks experienced noticeable blood pressure reductions, while younger adults did not.A simple beetroot juice routine may help explain one of the more surprising links in healthy aging: the connection between bacteria in the mouth and blood pressure. Research from the University of Exeter found that older adults who drank nitrate rich beetroot juice twice a day for two weeks saw their blood pressure fall. The same effect did not appear in younger adults, even though beetroot juice also changed their oral microbiome. The study, published in Free Radical Biology and Medicine, is the largest of its kind to examine how dietary nitrate affects the mouth bacteria, nitric oxide biology, and blood vessel responses of younger and older adults. Why the Mouth Matters Nitrate is found naturally in many vegetables and plays an important role in the body. Beetroot is especially rich in nitrate, but it is not the only option. Spinach, arugula, fennel, celery, and kale are also good dietary sources. The key step happens before nitrate reaches the bloodstream. Certain bacteria in the mouth help convert nitrate from food into compounds that eventually support the production of nitric oxide. Nitric oxide helps blood vessels relax and function properly, which is important for healthy blood pressure regulation. When the balance of oral bacteria shifts in the wrong direction, that nitrate to nitric oxide pathway may become less efficient. The Exeter team found evidence that beetroot juice changed the oral microbiome in older adults in a way that appeared to support this pathway. A Two Week Beetroot Juice Test The trial included 39 adults under age 30 and 36 adults in their 60s and 70s, recruited through the NIHR Exeter Clinical Research Facility. It was supported by the Exeter Clinical Trials Unit and funded through a BBSRC Industrial Partnership Award. Participants completed two separate two week phases. In one phase, they drank regular doses of nitrate rich beetroot juice. In the other, they drank a placebo version of the juice with the nitrate removed. A two week "wash out" period separated the phases so the researchers could reset the conditions before testing the next drink. The team then used bacterial gene sequencing to study which microbes were present in the mouth before and after each condition. Older Adults Responded Differently Both age groups showed significant changes in the oral microbiome after drinking nitrate rich beetroot juice. However, the changes were not the same in younger and older participants. Among older adults, beetroot juice was linked to a notable drop in Prevotella, a group of mouth bacteria that the researchers described as potentially harmful in this context. At the same time, bacteria associated with health benefits, including Neisseria, became more abundant. The older group also began the study with higher average blood pressure than the younger group. After the nitrate rich beetroot juice phase, their blood pressure fell. That reduction was not seen after the placebo drink, and it was not observed in the younger adults. The Nitric Oxide Connection The results point to a possible reason beetroot juice may be especially useful later in life. Older adults tend to produce less nitric oxide as they age, and reduced nitric oxide availability can affect blood vessel function. Study author Professor Anni Vanhatalo, of the University of Exeter, said: "We know that a nitrate-rich diet has health benefits, and older people produce less of their own nitric oxide as they age. They also tend to have higher blood pressure, which can be linked to cardiovascular complications like heart attack and stroke. Encouraging older adults to consume more nitrate-rich vegetables could have significant long term health benefits. The good news is that if you don't like beetroot, there are many nitrate-rich alternatives like spinach, rocket, fennel, celery and kale." The findings suggest that beetroot juice may not act only through the nutrients it delivers. It may also work by changing the tiny ecosystem in the mouth that helps unlock those nutrients. Related Research Adds to the Picture Follow up work and related studies have continued to strengthen the idea that oral bacteria are central to how nitrate affects the body. A 2025 randomized, double blind, placebo controlled crossover study of 15 older adults with treated high blood pressure found that four weeks of nitrate rich beetroot juice selectively changed the oral microbiome, increasing Neisseria and decreasing Veillonella, while the intestinal microbiome did not significantly change. The same research program reported that nitrate intake affected nitrate metabolism but did not produce sustained improvements in blood pressure or vascular function in that treated hypertension group, showing that the response may depend on health status, medications, study design, and the bacteria present at baseline. A 2026 pilot study also highlighted the importance of the mouth in nitrate biology. It found that chlorhexidine, an antiseptic mouthwash, disrupted nitrate processing and reduced gastric nitric oxide synthesis, while dietary nitrate supplementation partly preserved microbial function and nitric oxide related signaling during antiseptic use. Other work has raised similar questions about antibacterial mouth rinses. A 2025 Scientific Reports study in rats found that a nitrate and antioxidant mouth rinse supported nitrate and nitrite reducing oral bacteria and was associated with lower blood pressure compared with chlorhexidine treatment. Because that study was conducted in animals, the findings cannot be directly applied to people, but they add to the broader evidence that oral bacteria can influence the nitrate pathway. A Potential Nutrition Strategy for Healthy Aging Co-author Professor Andy Jones, of the University of Exeter, said: "This study shows that nitrate-rich foods alter the oral microbiome in a way that could result in less inflammation, as well as a lowering of blood pressure in older people. This paves the way for larger studies to explore the influence of lifestyle factors and biological sex in how people respond to dietary nitrate supplementation." The findings do not mean beetroot juice is a replacement for medication or other proven ways to manage blood pressure. However, they do suggest that nitrate rich vegetables could be a practical addition to a heart healthy lifestyle, particularly for older adults. They also point to a more personalized future for nutrition. Two people can eat the same nitrate rich foods but respond differently, partly because their oral microbiomes may not process nitrate in the same way. What Comes Next The Exeter researchers say larger studies are needed to understand why some people respond more strongly than others. Future research may help reveal how lifestyle, sex, age, oral hygiene habits, and baseline microbiome differences shape the effects of dietary nitrate. Dr. Lee Beniston FRSB, Associate Director for Industry Partnerships and Collaborative Research and Development at BBSRC, said: "This research is a great example of how bioscience can help us better understand the complex links between diet, the microbiome and healthy aging. By uncovering how dietary nitrate affects oral bacteria and blood pressure in older adults, the study opens up new opportunities for improving vascular health through nutrition. BBSRC is proud to have supported this innovative partnership between academic researchers and industry to advance knowledge with real-world benefits." Together, the evidence points to a striking idea: one path to healthier blood vessels may begin not in the heart, but in the mouth.

临床结果

2026-05-11

·medicoswab.com

Why MEIDIKE GENE Stands Out Among Medical Consumables Manufacturers

In the rapidly evolving healthcare and diagnostic industry, choosing a reliable medical consumables manufacturer is essential for ensuring product quality, testing accuracy, and patient safety. Hospitals, laboratories, diagnostic companies, and distributors worldwide are seeking trusted suppliers that offer high-quality products, stable production capacity, and flexible OEM/ODM services. As a professional Chinese manufacturer of medical consumables, MEIDIKE GENE provides comprehensive specimen collection and laboratory consumable solutions for global customers. MEIDIKE GENE, a brand of Medico Technology Co., Ltd., specializes in the research, development, and manufacturing of medical consumables and diagnostic sampling products. With years of industry experience, advanced production facilities, and strict quality management systems, the company supplies reliable products to customers in healthcare, diagnostics, biotechnology, pharmaceutical, and laboratory industries worldwide. The company supports both OEM and ODM customization services, helping distributors, brands, laboratories, and medical institutions develop customized products and private-label solutions. MEIDIKE GENE manufactures a wide range of specimen collection swabs designed for clinical diagnostics, microbiological testing, genetic testing, and laboratory sampling. Main products include: Flocked Swabs Foam Swabs Rayon Swabs Cotton Swabs Polyester Swabs These swabs are widely used for: Nasopharyngeal sampling Oropharyngeal sampling Cervical specimen collection DNA sample collection Environmental sampling Laboratory testing To meet the growing demand for diagnostic testing and home sample collection, MEIDIKE GENE offers various specimen collection kits for different applications. Virus Transport Medium (VTM) kits are designed for safe collection, transportation, and preservation of virus specimens. Applications include: Respiratory virus testing Influenza testing COVID-19 testing Molecular diagnostics DNA collection kits provide convenient and non-invasive sample collection for genetic testing, forensic testing, and research applications. HPV collection kits are specially designed for cervical screening and HPV testing. The kits can include cervical sampling brushes, collection tubes, and preservation solutions. Saliva collection kits are suitable for: Genetic testing DNA analysis Drug testing Research applications Stool specimen collection kits are commonly used for microbiome research, gastrointestinal disease testing, and laboratory analysis. Urine collection kits provide hygienic and secure sample collection for diagnostic and laboratory testing. MEIDIKE GENE also manufactures infection prevention and skin preparation products, including: Chlorhexidine Applicators Antiseptic Swabs Alcohol Wipes These products are widely used in hospitals, clinics, surgical centers, and home healthcare environments for skin disinfection and infection control. The cervical cytology brush is designed for gynecological sampling and cervical cell collection. The ergonomic design helps improve patient comfort and sample collection efficiency, making it suitable for cervical cancer screening and HPV testing. MEIDIKE GENE provides high-quality Vacuum Blood Collection Tubes for clinical blood collection and laboratory analysis. Available tube types include: Serum Tubes EDTA Tubes Heparin Tubes Gel & Clot Activator Tubes Glucose Tubes The tubes are manufactured under strict quality standards to ensure accurate and reliable laboratory results. The company also offers various sample storage and transport solutions, including: Sample Storage Tubes Flip-Top Desiccant Vial Plastic Cryo Tube Urine Specimen Collection Cup Stool Collection Cup These products help ensure specimen integrity during transportation and storage. As an experienced medical consumables manufacturer from China, MEIDIKE GENE operates advanced production facilities and cleanroom manufacturing environments to ensure product consistency and quality. MEIDIKE GENE supports customized manufacturing solutions, including: Private Label Packaging Customized Product Design Customized Packaging Brand Logo Printing Custom Sampling Kits This makes the company an ideal partner for distributors, wholesalers, diagnostic brands, and healthcare companies. MEIDIKE GENE products are manufactured under strict international quality standards and have obtained certifications including: CE Certification FDA Certification ISO13485 Certification TGA Certification MDEL Certification MEIDIKE GENE products are exported to many countries and regions worldwide, serving hospitals, laboratories, diagnostic centers, research institutions, and medical distributors. If you are looking for a trusted medical consumables manufacturer with strong production capabilities, reliable quality, and professional OEM/ODM support, MEIDIKE GENE is your ideal partner. Visit the official website to learn more about products and customization services: www.medicoswab.com

诊断试剂

100 项与葡萄糖氯己定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00858	葡萄糖氯己定	A01AB03 S03AA04 S02AA09	DB00878

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
牙周炎	美国	Dexcel Pharma Technologies Ltd.	1998-05-15
感染	澳大利亚	Bridgewest Perth Pharma Pty Ltd.	1991-08-13
细菌性皮肤疾病	澳大利亚	Bridgewest Perth Pharma Pty Ltd.	1991-08-13
牙龈疾病	美国	Solventum Corp.	1986-08-13
牙龈出血	美国	Solventum Corp.	1986-08-13
牙龈炎	美国	Solventum Corp.	1986-08-13
细菌感染	美国	Mölnlycke Health Care AB	1976-09-17
消毒剂	日本	Sumitomo Pharma Co., Ltd.	1959-09-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
种植体周围炎	临床3期	美国	Dexcel Pharma Technologies Ltd.	2014-07-01
种植体周围炎	临床3期	德国	Dexcel Pharma Technologies Ltd.	2014-07-01
种植体周围炎	临床3期	以色列	Dexcel Pharma Technologies Ltd.	2014-07-01
种植体周围炎	临床3期	英国	Dexcel Pharma Technologies Ltd.	2014-07-01
慢性牙周炎	临床3期	以色列	Dexcel Pharma Technologies Ltd.	2010-12-01
呼吸机相关性肺炎	临床阶段不明	美国	-	2010-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02572791 (SHINE, CTgov)	临床4期	细菌性皮肤疾病 \| 耐甲氧西林金黄色葡萄球菌感染	835	Chlorhexidine+Mupirocin (Periodic Personal Decolonization)	獵網獵糧積糧構憲願廠 = 醖壓獵遞積廠糧蓋積餘選夢獵鏇選衊顧顧獵廠 (醖鏇壓網簾選醖夢鑰願, 鬱觸構願壓鬱觸顧鏇齋 ~ 簾築構餘範夢膚簾鏇鬱) 更多	-	2026-02-24
				Household cleaning+Chlorhexidine+Mupirocin (Integrated Personal/Household Hygiene)	獵網獵糧積糧構憲願廠 = 網膚繭簾淵夢壓積憲獵選夢獵鏇選衊顧顧獵廠 (醖鏇壓網簾選醖夢鑰願, 範夢網構蓋鑰窪鹽遞窪 ~ 餘窪積襯鑰鹹壓餘觸繭) 更多
NCT05110001 (REAGIR, CTgov)	临床3期	棘阿米巴角膜炎 \| 真菌性角膜炎	330	Placebo+Chlorhexidine Gluconate+Moxifloxacin Ophthalmic+Natamycin (Standard Therapy)	蓋顧選願窪積憲製積願(網構獵選簾糧壓憲願夢) = 糧選壓鹽顧壓憲獵鏇艱醖願憲衊蓋蓋築壓鏇醖 (範艱積淵艱積遞鑰網鹹, 0.658) 更多	-	2026-01-30
				Chlorhexidine Gluconate+Rose Bengal+Moxifloxacin Ophthalmic+Natamycin (Cross-Linking With Rose Bengal (RB-PDT))	蓋顧選願窪積憲製積願(網構獵選簾糧壓憲願夢) = 蓋廠鹹網願夢選夢餘繭醖願憲衊蓋蓋築壓鏇醖 (範艱積淵艱積遞鑰網鹹, 0.675) 更多
NCT03503370 (CTgov)	临床2期	糖尿病足溃疡	175	Chlorhexidine (Chlorhexidine)	繭齋淵觸齋製膚鹽構獵 = 憲齋廠鑰範顧網築獵鏇範夢積鹹壓鑰築糧廠鏇 (鑰願膚壓衊鑰鑰簾獵製, 網餘淵淵獵獵築鑰窪獵 ~ 醖醖淵憲顧遞鏇窪淵廠) 更多	-	2024-08-09
				Placebo (Placebo)	繭齋淵觸齋製膚鹽構獵 = 淵醖壓網淵夢獵壓獵築範夢積鹹壓鑰築糧廠鏇 (鑰願膚壓衊鑰鑰簾獵製, 願壓窪憲遞構遞鏇廠構 ~ 鹹築醖衊鹽繭願鏇鏇繭) 更多
NCT03326726 (CTgov)	临床2期	-	30	chlorhexidine gluconate	鹹鹹襯蓋願糧醖憲觸範(蓋構襯糧淵積鏇淵衊蓋) = 鏇鏇鏇積齋範壓醖繭簾窪淵積選構蓋醖鬱醖蓋 (衊鏇簾繭齋膚襯窪鬱鹽, 0.0013) 更多	-	2023-09-28
NCT03385304 (Aqueous-PREP, CTgov)	临床4期	手术伤口感染 \| 开放性骨折	1,638	povidone-iodine+chlorhexidine gluconate (10% Povidone-iodine (1% Free Iodine) in Purified Water)	淵齋壓顧製蓋廠鏇襯窪 = 顧鑰選齋範餘鹹餘醖憲壓膚鬱窪壓遞鹽鬱顧夢 (積窪簾襯製廠廠夢製鏇, 製獵餘餘艱積選窪網膚 ~ 醖鏇簾鬱積觸鏇簾範構) 更多	-	2023-03-31
				povidone-iodine+chlorhexidine gluconate (4% Chlorhexidine Gluconate (CHG) in Purified Water)	淵齋壓顧製蓋廠鏇襯窪 = 鹹齋獵襯築遞獵醖顧蓋壓膚鬱窪壓遞鹽鬱顧夢 (積窪簾襯製廠廠夢製鏇, 簾艱獵選範觸鑰選廠選 ~ 製齋願艱簾淵範衊襯鏇) 更多
NCT03423147 (PRACTICAL, CTgov)	临床2期	手术伤口感染 \| 交叉感染	319	Chlorhexidine gluconate (Chlorhexidine Gluconate Vaginal Scrub and Cloth)	壓艱繭衊獵廠構獵襯襯 = 願淵鹽鹽餘壓遞窪鑰窪遞襯構製築簾餘願襯醖 (鹽鑰夢積網鹽遞糧網築, 齋遞鹽夢艱壓鹽膚範鏇 ~ 襯鬱範齋鏇鏇網廠範觸) 更多	-	2023-03-23
				2% chlorhexidine gluconate cloth (Standard Treatment)	壓艱繭衊獵廠構獵襯襯 = 齋蓋壓積築繭膚鬱顧膚遞襯構製築簾餘願襯醖 (鹽鑰夢積網鹽遞糧網築, 顧築顧選積餘選鹽艱膚 ~ 製選廠簾積艱積鹽醖鹽) 更多
NCT03883828 (ASCO2022) 人工标引	临床2/3期	放射性皮炎	76	mupirocin+Chlorhexidine gluconate	壓鹹顧窪鹹齋夢網鹹淵(膚鬱鏇選繭繭醖鹽淵壓) = 醖糧醖遞壓壓鑰獵淵簾廠選獵積餘齋糧糧鑰醖 (築鑰膚鹽糧選鹽願鏇鑰 ) 更多	积极	2022-06-08
				standard of care	壓鹹顧窪鹹齋夢網鹹淵(膚鬱鏇選繭繭醖鹽淵壓) = 鏇膚衊艱膚鬱觸鬱獵鏇廠選獵積餘齋糧糧鑰醖 (築鑰膚鹽糧選鹽願鏇鑰 ) 更多
NCT04748783 (COL, CTgov)	临床2期	新型冠状病毒感染	2	Water (Sterile Water)	糧窪憲夢範簾鏇蓋製願(鹽範壓淵鬱憲膚壓窪網) = 積顧觸鬱願選簾蓋餘構壓壓繭襯壓選醖齋鏇遞 (獵齋淵選築顧壓製觸襯, 餘願廠壓齋積膚糧鹽願 ~ 鹹壓壓範衊顧鹹鹽網鹹) 更多	-	2022-02-16
				Peroxyl (Peroxyl)	糧窪憲夢範簾鏇蓋製願(鹽範壓淵鬱憲膚壓窪網) = 蓋獵餘壓齋鹽鬱鹽衊繭壓壓繭襯壓選醖齋鏇遞 (獵齋淵選築顧壓製觸襯, 膚餘構夢鬱鑰鏇鏇願獵 ~ 獵糧鏇鹹範糧鑰糧構選) 更多
NCT02395614 (CTgov)	N/A	手术伤口感染 \| 乳腺癌	88	Chlorhexidine irrigation (Chlorhexidine Irrigation)	衊鬱齋觸鹹鹽範鹽窪築(醖壓製鑰憲繭願鬱衊願) = 壓簾糧艱鏇顧糧願夢鏇鬱艱衊廠壓廠獵壓鹽糧 (淵範積製淵鏇窪製鹹製, 鑰簾窪餘選醖觸膚鬱鏇 ~ 廠鑰鏇鑰糧淵鬱餘廠鏇) 更多	-	2022-01-26
				cefazolin+bacitracin+gentamicin (Triple Antibiotic Irrigation)	衊鬱齋觸鹹鹽範鹽窪築(醖壓製鑰憲繭願鬱衊願) = 膚夢鹹鬱網窪鬱壓淵艱鬱艱衊廠壓廠獵壓鹽糧 (淵範積製淵鏇窪製鹹製, 夢選製蓋膚願壓鹹積網 ~ 鑰齋醖繭餘簾簾膚蓋齋) 更多
NCT04373421 (CTgov)	临床4期	术后并发症	90	Chlorhexidine Gluconate+benzydamine hydrochloride (Chlorhexidine Gluconate Plus Benzydamine Hydrochloride)	衊製積鹽廠選簾糧範窪(艱憲製淵觸構構糧鑰簾) = 餘繭齋顧獵餘獵築構鹹衊壓製夢鬱範壓遞獵構 (鹹鏇築簾艱醖觸製廠鬱, 21.9) 更多	-	2021-11-01
				St. John's wort oil (St. John's Wort Oil)	衊製積鹽廠選簾糧範窪(艱憲製淵觸構構糧鑰簾) = 糧餘醖遞齋獵鹽衊網鏇衊壓製夢鬱範壓遞獵構 (鹹鏇築簾艱醖觸製廠鬱, 24.1) 更多